


# Coumarin-Palladium(II) Complex Acts as a Potent and Non-Toxic Anticancer Agent against Pancreatic Carcinoma Cells




Aleksandra Krstić<sup>1</sup>, Aleksandar Pavić<sup>1</sup>, Vanda Balint<sup>1</sup>, Stefan Lazić<sup>1</sup>, Edina Avdović<sup>2</sup>, Zoran Marković<sup>2</sup>, Jelena Pejić<sup>1</sup>, Milena Stevanović<sup>1,3,4</sup>, Isidora Petrović<sup>1\*</sup>

<sup>1</sup> Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade, Serbia;  
<sup>2</sup> Department of Science, Institute of Information Technologies, University of Kragujevac, Kragujevac, Serbia;  
<sup>3</sup> Faculty of Biology, University of Belgrade, Belgrade, Serbia;  
<sup>4</sup> Department of Chemical and Biological Sciences, Serbian Academy of Sciences and Arts, Belgrade, Serbia  
\*Correspondence: isidorapetrovic@imgge.bg.ac.rs; Tel.: +381-11-3976212


**Abstract:** Pancreatic carcinoma still represents one of the most lethal malignant diseases in the world although some progress has been made in treating the disease in the past decades. Current multiagent treatment options have improved the overall survival of patients, however, more effective treatment strategies are still needed. In this paper we have characterized the anticancer potential of coumarin-palladium(II) complex (C1) against pancreatic carcinoma cells. Cells viability, colony formation and migratory potential of pancreatic carcinoma cells were assessed *in vitro*, followed by evaluation of apoptosis induction and *in vivo* testing on zebrafish. Presented results showed remarkable reduction in pancreatic carcinoma cells growth *both in vitro* and *in vivo*, being effective at micromolar concentrations (0.5  $\mu$ M). Treatments induced apoptosis, increased BAX/BCL-2 ratio and suppressed the expression of *SOX9* and *SOX18*, genes shown to be significantly up-regulated in pancreatic ductal adenocarcinoma. Importantly, treatments of the zebrafish-pancreatic adenocarcinoma xenografts resulted in significant reduction in tumor mass, without provoking any adverse toxic effects including hepatotoxicity. Presented results indicate the great potential of the tested compound and the perspective of its further development towards pancreatic cancer therapy.




**Figure 1.** Schematic representation of the general procedure for the synthesis of complex Bis (3-(1-((3-hydroxyphenyl) amino)ethylidene) chroman-2,4-dione-palladium(II) complex (C1)



**Figure 2.** Effects of complex C1 on pancreatic carcinoma cells viability and potential to form colonies




**Figure 3.** Effect of complex C1 on PANC-1 cell's migratory potential




**Figure 4.** Pro-apoptotic effect of complex C1 on PANC-1 cells.

Complex C1 is able to induce cell death in PANC-1 cells partially by inducing apoptosis, whereas doxorubicin in the same experimental conditions exerts pro-necrotic activity. We observed apoptosis that is, at least in part, governed by increase in *BAX* and decrease in *BCL-2* expression in PANC-1 p53 mutated background.



**Figure 5.** Effect of complex C1 on selected SOX genes expression

Complex C1 successfully reduces *SOX9* and *SOX18* expression, showing the potential of complex C1 to target expression of these genes previously shown to be significantly up-regulated in PDAC samples.



**Figure 6.** Anticancer activity of complex C1 against human PANC-1 cells in zebrafish and *in vivo* hepatotoxicity

Complex C1 was very effective in reducing tumor growth in zebrafish xenograft model and, importantly, showing no signs of hepatotoxicity in zebrafish, marking this compound as non-toxic and a safe agent, with promising anticancer activity.